{"id":119640,"title":"Celadon Pharmaceuticals PLC (AIM:CEL) soared over 25% after finance update","publisher":"Share Talk","author":"sharetalk","published":"2025-02-12T11:27:50+00:00","modified":"2025-02-12T11:27:50+00:00","canonical_url":"https://www.share-talk.com/celadon-pharmaceuticals-plc-aimcel-soared-over-25-after-finance-update/","markdown_url":"https://www.share-talk.com/celadon-pharmaceuticals-plc-aimcel-soared-over-25-after-finance-update.md","json_url":"https://www.share-talk.com/celadon-pharmaceuticals-plc-aimcel-soared-over-25-after-finance-update.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["CANNABIS","CBD","CEL","Celadon Pharmaceuticals","cultivation","hydroponic","medicines","product"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/02/GhZhMIuWkAAFMal.webp?fit=680%2C381&quality=80&ssl=1","format":"news","language":"en-GB","content":"Shares in **Celadon Pharmaceuticals PLC (AIM: CEL)**, a UK-based pharmaceutical company specialising in cannabis-based medicines, surged over 25% in early trading following a financial update.\n\nThe company informed investors that it had drawn £1 million from its existing credit facility—marking the final withdrawal under this arrangement—and received a £389,000 tax credit.\n\nThe tax credit, linked to an R&D claim for the financial year ending December 2022, had previously been recorded as a deferred asset on its balance sheet.\n\nIn a brief statement, the company is actively exploring additional capital opportunities.\n\nIn London trading, shares rose 28% to 23p, giving the company a market valuation of over £15 million.\n\n**About Celadon Pharmaceuticals Plc**\n\nCeladon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon’s Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.\n\nFor further information please visit our website [www.celadonpharma.com](http://www.celadonpharma.com/)"}